{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:12:56Z","timestamp":1791972776901,"version":"4.3.4"},"reference-count":141,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Neuroendocrine tumors (NETs) are a heterogeneous class of cancers, predominately occurring in the gastroenteropancreatic system, which pose a growing health concern with a significant rise in incidence over the past four decades. Emerging from neuroendocrine cells, these tumors often elicit paraneoplastic syndromes such as carcinoid syndrome, which can manifest as a constellation of symptoms significantly impacting patients\u2019 quality of life. The prognosis of NETs is influenced by their tendency for metastasis, especially in cases involving the liver, where the estimated 5-year survival is between 20 and 40%. Although surgical resection remains the preferred curative option, challenges emerge in cases of neuroendocrine tumors with liver metastasis (NELM) with multifocal lobar involvement, and many patients may not meet the criteria for surgery. Thus, minimally invasive and non-surgical treatments, such as locoregional therapies, have surfaced. Overall, these approaches aim to prioritize symptom relief and aid in overall tumor control. This review examines locoregional therapies, encompassing catheter-driven procedures, ablative techniques, and radioembolization therapies. These interventions play a pivotal role in enhancing progression-free survival and managing hormonal symptoms, contributing to the dynamic landscape of evolving NELM treatment. This review meticulously explores each modality, presenting the current state of the literature on their utilization and efficacy in addressing NELM.<\/jats:p>","DOI":"10.3390\/curroncol31040154","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T08:27:52Z","timestamp":1712305672000},"page":"2076-2091","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management"],"prefix":"10.3390","volume":"31","author":[{"given":"Cody R.","family":"Criss","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, OhioHealth Riverside Methodist Hospital, Columbus, OH 43214, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-7132","authenticated-orcid":false,"given":"Mina S.","family":"Makary","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, OH 43240, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.hpb.2022.06.009","article-title":"Treatment Strategies for Neuroendocrine Liver Metastases: A Systematic Review","volume":"24","author":"Muttillo","year":"2022","journal-title":"HPB"},{"key":"ref_4","first-page":"637","article-title":"The Malignant Carcinoid Syndrome","volume":"137","author":"Davis","year":"1973","journal-title":"Surg. Gynecol. Obs."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-Syndrome: Recent Advances, Current Status and Controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid Syndrome: Update on the Pathophysiology and Treatment","volume":"73","author":"Glasberg","year":"2018","journal-title":"Clinics"},{"key":"ref_7","unstructured":"Ihse, I., Lindell, G., and Tibblin, S. (2001). Surgical Treatment: Evidence-Based and Problem-Oriented, Zuckschwerdt."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00316983","article-title":"Neuroendocrine Metastases of the Liver","volume":"19","author":"Ihse","year":"1995","journal-title":"World J. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.amjsurg.2023.08.011","article-title":"Management of Neuroendocrine Tumor Liver Metastases","volume":"226","author":"Harrelson","year":"2023","journal-title":"Am. J. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The Epidemiology of Metastases in Neuroendocrine Tumors","volume":"139","author":"Hemminki","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.livres.2018.08.002","article-title":"Neuroendocrine Tumors with Hepatic Metastases: A Review of Evolving Treatment Options","volume":"2","author":"Colquhoun","year":"2018","journal-title":"Liver Res."},{"key":"ref_14","first-page":"130","article-title":"Currently Available Treatment Options for Neuroendocrine Liver Metastases","volume":"34","author":"Machairas","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within Patients with Gastroenteropancreatic Neuroendocrine Tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2214\/AJR.21.27159","article-title":"Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response\u2014AJR Expert Panel Narrative Review","volume":"218","author":"Galgano","year":"2022","journal-title":"Am. J. Roentgenol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Carideo, L., Prosperi, D., Panzuto, F., Magi, L., Pratesi, M.S., Rinzivillo, M., Annibale, B., and Signore, A. (2019). Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET\/CT in the Management of GEP-NENs: A Systematic Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071032"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","article-title":"18F-Fluorodihydroxyphenylalanine vs Other Radiopharmaceuticals for Imaging Neuroendocrine Tumours According to Their Type","volume":"40","author":"Balogova","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1148\/radiol.12120495","article-title":"Neuroendocrine Liver Metastasis Treated by Using Intraarterial Therapy: Volumetric Functional Imaging Biomarkers of Early Tumor Response and Survival","volume":"266","author":"Bonekamp","year":"2013","journal-title":"Radiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12105-022-01435-8","article-title":"Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms","volume":"16","author":"Mete","year":"2022","journal-title":"Head Neck Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40644-023-00556-9","article-title":"Diagnostic Performance of PET\/CT in the Detection of Liver Metastases in Well-Differentiated NETs","volume":"23","author":"Grawe","year":"2023","journal-title":"Cancer Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/bjs.6468","article-title":"Treatment of Liver Metastases from Neuroendocrine Tumours in Relation to the Extent of Hepatic Disease","volume":"96","author":"Frilling","year":"2009","journal-title":"Br. J. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical Treatment of Neuroendocrine Metastases to the Liver: A Plea for Resection to Increase Survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J. Am. Coll. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mahuron, K.M., and Singh, G. (2023). Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072456"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.5306\/wjco.v12.i9.725","article-title":"Metastatic Disease to the Liver: Locoregional Therapy Strategies and Outcomes","volume":"12","author":"Zane","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11864-023-01124-w","article-title":"The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors","volume":"24","author":"Citterio","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.21037\/hbsn.2020.04.02","article-title":"Neuroendocrine Liver Metastases: A Contemporary Review of Treatment Strategies","volume":"9","author":"Cloyd","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40265-018-1033-0","article-title":"Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives","volume":"79","author":"Hofland","year":"2019","journal-title":"Drugs"},{"key":"ref_30","first-page":"70","article-title":"Octreotide\u2014A Review of Its Use in Treating Neuroendocrine Tumours","volume":"10","author":"Costa","year":"2014","journal-title":"Eur. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Milewska-Kranc, A., \u0106wik\u0142a, J.B., and Kolasinska-\u0106wik\u0142a, A. (2023). The Role of Receptor\u2013Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors. Cancers, 16.","DOI":"10.3390\/cancers16010116"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Stueven, A.K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B., Roderburg, C., and Jann, H. (2019). Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123049"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Camus, B., Cottereau, A.-S., Palmieri, L.-J., Dermine, S., Tenenbaum, F., Brezault, C., and Coriat, R. (2021). Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061267"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus Long-Acting Octreotide versus High-dose Long-Acting Octreotide in Patients with Midgut Neuroendocrine Tumours (NETTER-1): Final Overall Survival and Long-Term Safety Results from an Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS Treatment Guidelines","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/MPA.0000000000001597","article-title":"The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Halfdanarson","year":"2020","journal-title":"Pancreas"},{"key":"ref_41","unstructured":"(2023). North American Neuroendocrine Tumor Society Consensus Guidelines, NANETS."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"941832","DOI":"10.3389\/fendo.2022.941832","article-title":"The Evolution of PRRT for the Treatment of Neuroendocrine Tumors; What Comes Next?","volume":"13","author":"Harris","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"viii478","DOI":"10.1093\/annonc\/mdy293.028","article-title":"COMPETE Trial: Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide vs. Everolimus in Progressive GEP-NET","volume":"29","author":"Pavel","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide Receptor Radionuclide Therapy Combinations for Neuroendocrine Tumours in Ongoing Clinical Trials: Status 2023","volume":"14","author":"Santo","year":"2024","journal-title":"Theranostics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ejso.2018.12.022","article-title":"Surgical Resection of Neuroendocrine Tumor Liver Metastases as Part of Multimodal Treatment Strategies: A Propensity Score Matching Analysis","volume":"45","author":"Schreckenbach","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2217\/hep-2017-0014","article-title":"Locoregional Therapies in Cholangiocarcinoma","volume":"4","author":"Labib","year":"2017","journal-title":"Hepat. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Makary, M.S., Khandpur, U., Cloyd, J.M., Mumtaz, K., and Dowell, J.D. (2020). Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers, 12.","DOI":"10.3390\/cancers12071914"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional Therapies in the Era of Molecular and Immune Treatments for Hepatocellular Carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00270-022-03072-8","article-title":"TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC","volume":"45","author":"Guiu","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e220206","DOI":"10.1530\/ERC-22-0206","article-title":"Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the Management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms","volume":"30","author":"Eads","year":"2023","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11864-023-01152-6","article-title":"Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy","volume":"24","author":"Rabei","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000479293","article-title":"Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases","volume":"106","author":"Ronot","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-2008-1027555","article-title":"Neuroendocrine Tumors: Characterization with Contrast-Enhanced Ultrasonography","volume":"29","author":"Wermke","year":"2008","journal-title":"Ultraschall Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Miyayama, S. (2020). Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma. Appl. Sci., 10.","DOI":"10.3390\/app10207337"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ngongoni, R., and Visser, B. (2022). Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases. Cancers, 14.","DOI":"10.3390\/cancers14205103"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.4103\/jfmpc.jfmpc_2347_20","article-title":"A Review of Applying Transarterial Chemoembolization (TACE) Method for Management of Hepatocellular Carcinoma","volume":"10","author":"Ghanaati","year":"2021","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.2217\/fon-2018-0136","article-title":"DEB-TACE: A Standard Review","volume":"14","author":"Melchiorre","year":"2018","journal-title":"Future Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jvir.2016.05.014","article-title":"Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases","volume":"27","author":"Makary","year":"2016","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e5606","DOI":"10.1097\/MD.0000000000005606","article-title":"The Incidence and Outcome of Major Complication Following Conventional TAE\/TACE for Hepatocellular Carcinoma","volume":"95","author":"Tu","year":"2016","journal-title":"Medicine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial Chemoembolization vs. Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis","volume":"230","author":"Egger","year":"2020","journal-title":"J. Am. Coll. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Touloupas, C., Faron, M., Hadoux, J., Deschamps, F., Roux, C., Ronot, M., Yevich, S., Joskin, J., Gelli, M., and Barb\u00e9, R. (2021). Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers, 13.","DOI":"10.3390\/cancers13215366"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1007\/s12032-010-9750-6","article-title":"Hepatic Artery Chemoembolization for the Treatment of Liver Metastases from Neuroendocrine Tumors: A Long-Term Follow-up in 123 Patients","volume":"28","author":"Dong","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1245\/s10434-012-2786-4","article-title":"Extrahepatic Disease Should Not Preclude Transarterial Chemoembolization for Metastatic Neuroendocrine Carcinoma","volume":"20","author":"Arrese","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1245\/s10434-016-5591-7","article-title":"Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization Using Streptozotocin: A 20-Year Experience","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jss.2018.06.058","article-title":"Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases","volume":"232","author":"McDermott","year":"2018","journal-title":"J. Surg. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","article-title":"Intra-Arterial Therapy of Neuroendocrine Tumor Liver Metastases: Comparing Conventional TACE, Drug-Eluting Beads TACE and 90Yttrium Radioembolization as Treatment Options Using a Propensity Score Analysis Model","volume":"27","author":"Minh","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jvir.2013.02.030","article-title":"Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases","volume":"24","author":"Hur","year":"2013","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4240\/wjgs.v14.i2.78","article-title":"Therapeutic Strategies for Gastroenteropancreatic Neuroendocrine Neoplasms: State-of-the-Art and Future Perspectives","volume":"14","author":"Merola","year":"2022","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-14-0630","article-title":"GEP-NETS Update: Interventional Radiology: Role in the Treatment of Liver Metastases from GEP-NETs","volume":"172","author":"Deschamps","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13063-018-2782-5","article-title":"Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): Study Protocol for a Randomized Controlled Trial","volume":"19","author":"Chen","year":"2018","journal-title":"Trials"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.acra.2023.03.042","article-title":"Clinical Outcomes of DEB-TACE in Hepatic Metastatic Neuroendocrine Tumors: A 5-Year Single-Institutional Experience","volume":"30","author":"Makary","year":"2023","journal-title":"Acad. Radiol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Barat, M., Cottereau, A.-S., Kedra, A., Dermine, S., Palmieri, L.-J., Coriat, R., Dautry, R., Tselikas, L., Soyer, P., and Dohan, A. (2020). The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072302"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","article-title":"Transarterial Embolization (TAE) Is Equally Effective and Slightly Safer than Transarterial Chemoembolization (TACE) to Manage Liver Metastases in Neuroendocrine Tumors","volume":"47","author":"Fiore","year":"2014","journal-title":"Endocrine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.3747\/co.27.6205","article-title":"Comparison of Transarterial Bland and Chemoembolization for Neuroendocrine Tumours: A Systematic Review and Meta-Analysis","volume":"27","author":"Tai","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","article-title":"Hepatic Artery Embolization in Advanced Neuroendocrine Tumors: Efficacy and Long-Term Outcomes","volume":"12","author":"Pericleous","year":"2016","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/sj.bjc.6601329","article-title":"Postchemoembolisation Syndrome--Tumour Necrosis or Hepatocyte Injury?","volume":"89","author":"Wigmore","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/NCC.0000000000000302","article-title":"Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer","volume":"39","author":"Blackburn","year":"2016","journal-title":"Cancer Nurs."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1148\/radiographics.18.3.9599386","article-title":"Complications Associated with Transcatheter Arterial Embolization for Hepatic Tumors","volume":"18","author":"Sakamoto","year":"1998","journal-title":"RadioGraphics"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1756-9966-33-43","article-title":"Hepatic Arterial Embolization in Patients with Neuroendocrine Tumors","volume":"33","author":"Fiore","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1067\/msy.2001.117377","article-title":"Indications and Results of Liver Resection and Hepatic Chemoembolization for Metastatic Gastrointestinal Neuroendocrine Tumors","volume":"130","author":"Yao","year":"2001","journal-title":"Surgery"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000485471","article-title":"Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit\/Risk Assessment","volume":"7","author":"Piscaglia","year":"2018","journal-title":"Liver Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/SLA.0b013e3181dbb7a7","article-title":"Liver-Directed Therapy for Hepatic Metastases in Patients Undergoing Pancreaticoduodenectomy: A Dual-Center Analysis","volume":"252","author":"Farnell","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.liver.2021.100063","article-title":"Cardiopulmonary Assessment of Patients with Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization","volume":"5","author":"Farid","year":"2022","journal-title":"J. Liver Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Xu, A., Suz, P., Reljic, T., Are, A.C., Kumar, A., Powers, B., Strosberg, J., Denbo, J.W., Fleming, J.B., and Anaya, D.A. (2022). Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. Cancers, 14.","DOI":"10.3390\/cancers14122966"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wong, T.Y., Zhang, K.S., Gandhi, R.T., Collins, Z.S., O\u2019Hara, R., Wang, E.A., Vaheesan, K., Matsuoka, L., Sze, D.Y., and Kennedy, A.S. (2022). Long-Term Outcomes Following 90Y Radioembolization of Neuroendocrine Liver Metastases: Evaluation of the Radiation-Emitting SIR-Spheres in Non-Resectable Liver Tumor (RESiN) Registry. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09302-z"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.jvir.2020.05.019","article-title":"Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization","volume":"31","author":"Currie","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-Induced Chronic Hepatotoxicity: A Single-Center Cohort Analysis","volume":"30","author":"Currie","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","article-title":"Additional Holmium-166 Radioembolisation after Lutetium-177-Dotatate in Patients with Neuroendocrine Tumour Liver Metastases (HEPAR PLuS): A Single-Centre, Single-Arm, Open-Label, Phase 2 Study","volume":"21","author":"Braat","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ramdhani, K., and Braat, A.J.A.T. (2022). The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers, 14.","DOI":"10.3390\/cancers14143415"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1477-2574.2012.00528.x","article-title":"Adjunctive Radiofrequency Ablation of Metastatic Neuroendocrine Cancer to the Liver Complements Surgical Resection","volume":"15","author":"Taner","year":"2013","journal-title":"HPB"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4","DOI":"10.17998\/jlc.2022.01.16","article-title":"Radioembolization for Hepatocellular Carcinoma: What Clinicians Need to Know","volume":"22","author":"Choi","year":"2022","journal-title":"J. Liver Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"d\u2019Abadie, P., Hesse, M., Louppe, A., Lhommel, R., Walrand, S., and Jamar, F. (2021). Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules, 26.","DOI":"10.3390\/molecules26133966"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s13139-021-00709-3","article-title":"Transarterial Radioembolization Agents: A Review of the Radionuclide Agents and the Carriers","volume":"55","author":"Alrfooh","year":"2021","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-0041-1735606","article-title":"Principles of Radioembolization","volume":"38","author":"Sivananthan","year":"2021","journal-title":"Semin. Interv. Radiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7861\/clinmedicine.17-5-449","article-title":"Selective Internal Radiation Therapy for Liver Tumours","volume":"17","author":"Sundram","year":"2017","journal-title":"Clin. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00259-013-2674-6","article-title":"The Dosimetric Importance of the Number of 90Y Microspheres in Liver Transarterial Radioembolization (TARE)","volume":"41","author":"Spreafico","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","article-title":"Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)","volume":"44","author":"Helmberger","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.hpb.2018.12.014","article-title":"Radioembolisation with 90Y Microspheres for Neuroendocrine Liver Metastases: An Institutional Case Series, Systematic Review and Meta-Analysis","volume":"21","author":"Frilling","year":"2019","journal-title":"HPB"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 Radioembolization for Unresectable Metastatic Neuroendocrine Liver Tumor: A Systematic Review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur. J. Radiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1245\/s10434-020-09469-4","article-title":"Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-Analysis Comparing Clinical Outcomes","volume":"28","author":"Ngo","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21037\/jgo.2016.02.02","article-title":"Ki67 Score as a Potential Predictor in the Selection of Liver-Directed Therapies for Metastatic Neuroendocrine Tumors: A Single Institutional Experience","volume":"7","author":"Singla","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00428-013-1410-8","article-title":"Ki-67 Is a Reliable Pathological Grading Marker for Neuroendocrine Tumors","volume":"462","author":"Nadler","year":"2013","journal-title":"Virchows Arch."},{"key":"ref_109","first-page":"679","article-title":"90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study","volume":"63","author":"Schaarschmidt","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00270-014-0947-5","article-title":"Risk of Liver Abscess Formation in Patients with Prior Biliary Intervention Following Yttrium-90 Radioembolization","volume":"38","author":"Cholapranee","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/ijri.IJRI_240_19","article-title":"Microwave Ablation: How We Do It?","volume":"30","author":"Gala","year":"2020","journal-title":"Indian. J. Radiol. Imaging"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3348\/kjr.2000.1.4.175","article-title":"Radiofrequency Thermal Ablation of Hepatocellular Carcinomas","volume":"1","author":"Lim","year":"2000","journal-title":"Korean J. Radiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","article-title":"Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update","volume":"24","author":"Izzo","year":"2019","journal-title":"Oncologist"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jvir.2010.04.008","article-title":"Radiofrequency Ablation: Mechanism of Action and Devices","volume":"21","author":"Hong","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.sla.0000143301.56154.95","article-title":"Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation","volume":"240","author":"Mazzaferro","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave Tumor Ablation: Mechanism of Action, Clinical Results and Devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1148\/rg.25si055501","article-title":"Microwave Ablation: Principles and Applications","volume":"25","author":"Simon","year":"2005","journal-title":"Radiographics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4254\/wjh.v7.i8.1054","article-title":"Percutaneous Microwave Ablation vs Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma","volume":"7","author":"Poulou","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1097\/MD.0000000000000580","article-title":"Heat Sink Effect on Tumor Ablation Characteristics as Observed in Monopolar Radiofrequency, Bipolar Radiofrequency, and Microwave, Using Ex Vivo Calf Liver Model","volume":"94","author":"Pillai","year":"2015","journal-title":"Medicine"},{"key":"ref_120","first-page":"182","article-title":"Percutaneous Cryoablation for Liver Cancer","volume":"2","author":"Niu","year":"2014","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/radiology.179.3.2027979","article-title":"Liver Metastases: Results of Percutaneous Ethanol Injection in 14 Patients","volume":"179","author":"Livraghi","year":"1991","journal-title":"Radiology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1098-2388(199803)14:2<175::AID-SSU10>3.0.CO;2-2","article-title":"Cryotherapy for Neuroendocrine Liver Metastases","volume":"14","author":"Seifert","year":"1998","journal-title":"Semin. Surg. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4158\/EP-2019-0394","article-title":"Can Microwave Ablation Be an Alternative to Resection for the Treatment of Neuroendocrine Liver Metastases?","volume":"26","author":"Perrodin","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","article-title":"Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases: A 10-Year Experience Evaluating Predictors of Survival","volume":"142","author":"Mazzaglia","year":"2007","journal-title":"Surgery"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-Directed Surgery of Neuroendocrine Metastases: What Is the Optimal Strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jvir.2014.12.009","article-title":"Radiofrequency Ablation for Neuroendocrine Liver Metastases: A Systematic Review","volume":"26","author":"Mohan","year":"2015","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/lap.2020.0558","article-title":"Operative Microwave Ablation for the Multimodal Treatment of Neuroendocrine Liver Metastases","volume":"31","author":"Pickens","year":"2021","journal-title":"J. Laparoendosc. Adv. Surg. Tech. A"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e13289","DOI":"10.1111\/jne.13289","article-title":"Radiofrequency and Microwave Ablation Controls Hepatic Oligoprogression of Advanced Gastroenteropancreatic Neuroendocrine Tumors","volume":"35","author":"Matrood","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Cazzato, R.L., Hubel\u00e9, F., De Marini, P., Ouvrard, E., Salvadori, J., Addeo, P., Garnon, J., Kurtz, J.-E., Greget, M., and Mertz, L. (2021). Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. Cancers, 13.","DOI":"10.3390\/cancers13246368"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Yordanova, A., and Ahmadzadehfar, H. (2021). Combination Therapies with PRRT. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101005"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b Study of Pasireotide, Everolimus, and Selective Internal Radioembolization Therapy for Unresectable Neuroendocrine Tumors with Hepatic Metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13139-014-0292-2","article-title":"Sequential Use of 90Y Microspheres Radioembolization and 177Lu-Dotatate in Pluri-Metastatic Neuroendocrine Tumors: A Case Report","volume":"48","author":"Filippi","year":"2014","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_133","first-page":"1189","article-title":"Toxicity of Sequential Treatment with Radioembolization and PRRT in Hepatic Metastasized Neuroendocrine Tumors","volume":"53","author":"Geisler","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","article-title":"Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy","volume":"43","author":"Braat","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of Liver Tumour Burden, Alkaline Phosphatase Elevation, and Target Lesion Size on Treatment Outcomes with 177Lu-Dotatate: An Analysis of the NETTER-1 Study","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"46","DOI":"10.20517\/2394-5079.2018.49","article-title":"Screening for Hepatocellular Carcinoma: Summary of Current Guidelines up to 2018","volume":"4","author":"Yilmaz","year":"2018","journal-title":"Hepatoma Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2967\/jnumed.112.107482","article-title":"90Y Radioembolization after Radiation Exposure from Peptide Receptor Radionuclide Therapy","volume":"53","author":"Ezziddin","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"viii471","DOI":"10.1093\/annonc\/mdy293.009","article-title":"Impact of Liver Tumor Burden on Therapeutic Effect of 177Lu-Dotatate Treatment in NETTER-1 Study","volume":"29","author":"Strosberg","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13063-019-3888-0","article-title":"Intra-Arterial versus Standard Intravenous Administration of Lutetium-177-DOTA-Octreotate in Patients with NET Liver Metastases: Study Protocol for a Multicenter, Randomized Controlled Trial (LUTIA Trial)","volume":"21","author":"Ebbers","year":"2020","journal-title":"Trials"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00259-023-06467-y","article-title":"Intra-Arterial Peptide-Receptor Radionuclide Therapy for Neuro-Endocrine Tumour Liver Metastases: An in-Patient Randomised Controlled Trial (LUTIA)","volume":"51","author":"Ebbers","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00259-023-06581-x","article-title":"The LUTIA Trial: A Small Step for PRRT, a Giant Leap for Intra-Arterial Radionuclide Therapy Trial Methodology","volume":"51","author":"Deroose","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:23:49Z","timestamp":1760106229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":141,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["curroncol31040154"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31040154","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}